Clinical Trial Search

Primary: Proportion of Participants Alive and Without Mechanical Ventilation Through Day 29 in Participants With Baseline Ordinal Score of 5 or 6, C-reactive Protein…

Primary: Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6 — -1.4; -2.5 Units on a scale

Primary: Change From Baseline in Frequency of Spasm Clusters at Day 10 — 1.0; 2.7; -5.4; -1.0 Spasm clusters per day — p=0.7391

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to…

Primary: Number of Participants Experiencing Adverse Events in the Mifepristone Versus Placebo Group as a Measure of Safety and Tolerability — 0; 3 Participants — p=>.05

Primary: Number of Participants Experiencing the Incidence of Grade One or Higher Adverse Events — 12 participants

Primary: The Percentage of Participants With Grade 3 or Higher Treatment-related Adverse Events — 0; 0; 0; 0 Participants

Primary: Absolute Change in Inflammatory Lesion Counts — -7.7; -4.1; -11.2; -11.3 inflammatory acne lesions

Primary: Disease Response (RECIST) — NA days

Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05

Primary: Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment — 5.9; 11.1; 7.4; 14.8 Percentage of participants

Primary: For Viral Domain: Change in Viral Shedding — 1.6; 1.7; 1.0 cycles — p=0.20

Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants

Primary: Change From Baseline in Central Corneal Endothelial Cell Counts — -243.4; -184.8; -260.3 cells/mm^2 — p=0.4529

Primary: Change From Baseline in Intraocular Pressure at Day 28 (Study Eye) — -6.95; -7.95; -7.04 mmHg — p=0.8070